Breaking News, Collaborations & Alliances

iBio Enters AI Partnership with RubrYc Therapeutics

Secures option to license additional antibodies developed with RubrYc’s predictive algorithms.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

iBio, a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs). The partnership also includes an option agreement for iBio to license additional antibodies built using RubrYc’s artificial intelligence (AI)-based antibody discovery platform.   “We are pleased to add another pro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters